Frontlight ResearchEarly access
Taking peopleNo phase
T6A Biomarker for Detection of Bacterial Infection in Newborn Infants
Key facts
- Who runs it
- Salzburger Landeskliniken
- Where
- Austria and Poland2 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 210 people, planned
- Started
- 3 Sept 2026
- Expected to end
- 31 Jan 2029
- Type of study
- Observational, 2 groups
- Record updated
- 9 September 2026
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Newborn infants who require blood testing for screening for bacterial infection OR treating physician suspects bacterial infection in newborn infant
- Signed informed consent form
Who cannot take part
- Refusal to participate in study or not providing written informed consent by caregivers/parents
- Antibiotic treatment of any kind
This trial has no sites in United States.
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This bi-center study aims to assess the efficacy of a new biomarker, N6-threonylcarbamoyladenosine (t6A), for the early diagnosis of Early-Onset Sepsis (EOS) in newborns.
The 2 groups in the trial
- Patients
- Controls
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 9 September 2026